Savara (SVRA) Total Non-Current Liabilities (2016 - 2025)
Savara's (SVRA) quarterly Total Non-Current Liabilities came in at $50.3 million in Q4 2025, up 21.67% year-on-year from $41.3 million in Q4 2024, and up 8.09% on a QoQ basis from $46.5 million in Q3 2025.
Savara (SVRA) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends
Savara (SVRA) has 10 years of Total Non-Current Liabilities data on file, last reported at $50.3 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 21.67% year-over-year to $50.3 million in Q4 2025; TTM through Dec 2025 was $50.3 million, a 21.67% increase from a year earlier, with the FY2025 full-year figure at $50.3 million, up 21.67% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $50.3 million, up from $46.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for SVRA reached as high as $50.3 million in Q4 2025 and fell as low as $29.6 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $36.1 million across 5 years, with a median of $33.8 million in 2021.
- Across the five-year window, Total Non-Current Liabilities grew 21.73% in 2021 and slipped 8.69% in 2022, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $32.0 million in 2021, then slipped by 0.12% to $31.9 million in 2022, then gained by 15.65% to $36.9 million in 2023, then gained by 11.9% to $41.3 million in 2024, then rose by 21.67% to $50.3 million in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $50.3 million in Q4 2025, $46.5 million in Q3 2025, and $43.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.42 Mn |
| Dec 31, 2024 | 41.34 Mn |
| Sep 30, 2024 | 39.34 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 36.23 Mn |
| Dec 31, 2023 | 36.95 Mn |
| Sep 30, 2023 | 35.24 Mn |
| Jun 30, 2023 | 32.10 Mn |
| Mar 31, 2023 | 31.07 Mn |
| Dec 31, 2022 | 31.95 Mn |
| Sep 30, 2022 | 31.17 Mn |
| Jun 30, 2022 | 29.65 Mn |
| Mar 31, 2022 | 29.63 Mn |
| Dec 31, 2021 | 31.98 Mn |
| Sep 30, 2021 | 32.01 Mn |
| Jun 30, 2021 | 31.02 Mn |
| Mar 31, 2021 | 32.45 Mn |